Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries
Benzinga Newsdesk 9 months ago
News
The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration
- The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.
- This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i